Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Commercial Vehicle Group (CVGI)
Consensus Price Target: $7.17 (48.5% implied return)
Formed from a partnership between two distinct companies, CVG (NASDAQ:CVGI) offers various components used in vehicles and systems used in warehouses.
Why Should You Dump CVGI?
-
Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.5% annually over the last five years
-
Performance over the past five years was negatively impacted by new share issuances as its earnings per share dropped by 36.2% annually, worse than its revenue
-
Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
At $4.83 per share, Commercial Vehicle Group trades at 0.3x trailing 12-month price-to-sales. Read our free research report to see why you should think twice about including CVGI in your portfolio, it’s free.
AdaptHealth (AHCO)
Consensus Price Target: $14 (42.1% implied return)
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Why Are We Cautious About AHCO?
-
Sales were flat over the last two years, indicating it’s failed to expand this cycle
-
Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 12.4% annually
-
Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its shrinking returns suggest its past profit sources are losing steam
AdaptHealth’s stock price of $9.85 implies a valuation ratio of 10.3x forward P/E. Check out our free in-depth research report to learn more about why AHCO doesn’t pass our bar.
Amentum (AMTM)
Consensus Price Target: $33.50 (55.7% implied return)
With operations spanning approximately 80 countries and a workforce of specialized engineers and technical experts, Amentum Holdings (NYSE:AMTM) provides advanced engineering and technology solutions to U.S. government agencies, allied governments, and commercial enterprises across defense, energy, and space sectors.
Leave a comment